Skip to main
MDLN

Medline Inc (MDLN) Stock Forecast & Price Target

Medline Inc (MDLN) Analyst Ratings

Based on 23 analyst ratings
Buy
Strong Buy 35%
Buy 52%
Hold 13%
Sell 0%
Strong Sell 0%

Bulls say

Medline's sales revenue demonstrated robust growth, increasing 11.47% year-over-year from $25.51 billion to $28.43 billion for the 12 months ending December 2025, underscoring the company's strong market position and demand for its offerings. The return on capital has also shown positive momentum, rising from 7.22% to 7.44%, which reflects effective capital utilization and significant economic profit potential. Additionally, Medline's brand now represents nearly half of its revenue and over 80% of its segment, with noteworthy performance in Surgical Solutions, indicating a solid foundation for continued growth and profitability through enhanced unit economics and expanded distribution capabilities.

Bears say

Medline's economic profit saw a significant decline of 220.79% year-over-year, shifting from a gain of $345.1 million to a loss of $416.9 million, primarily attributed to the cost measurement following its IPO. Additionally, Net Operating Profit After Tax (NOPAT) fell by 12.66% year-over-year, from $2.45 billion to $2.14 billion, indicating pressure on profitability amid challenging market conditions. The company also faced a 4.48% decline in Economic Operating Cash Flow (EBITDAR), from $3.71 billion to $3.54 billion, compounded by low-margin operating environments and potential risks associated with maintaining Prime Vendor relationships and competition.

Medline Inc (MDLN) has been analyzed by 23 analysts, with a consensus rating of Buy. 35% of analysts recommend a Strong Buy, 52% recommend Buy, 13% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Medline Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Medline Inc (MDLN) Forecast

Analysts have given Medline Inc (MDLN) a Buy based on their latest research and market trends.

According to 23 analysts, Medline Inc (MDLN) has a Buy consensus rating as of Mar 25, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $50.48, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $50.48, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Medline Inc (MDLN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.